Insider Buying: Exagen Inc. (NASDAQ:XGN) CEO Acquires $77,569.92 in Stock

Exagen Inc. (NASDAQ:XGNGet Free Report) CEO John Aballi bought 40,401 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were bought at an average cost of $1.92 per share, for a total transaction of $77,569.92. Following the completion of the acquisition, the chief executive officer now directly owns 40,401 shares in the company, valued at approximately $77,569.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Exagen Trading Down 0.5 %

Shares of XGN opened at $1.88 on Friday. The company has a quick ratio of 4.02, a current ratio of 4.83 and a debt-to-equity ratio of 0.96. The firm’s fifty day simple moving average is $1.54 and its two-hundred day simple moving average is $1.75. Exagen Inc. has a 12 month low of $1.30 and a 12 month high of $3.47.

Exagen (NASDAQ:XGNGet Free Report) last issued its earnings results on Monday, March 18th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.02). The business had revenue of $13.77 million during the quarter, compared to the consensus estimate of $11.43 million. Exagen had a negative return on equity of 75.86% and a negative net margin of 34.74%. During the same quarter in the previous year, the firm posted ($0.58) earnings per share. Equities analysts expect that Exagen Inc. will post -1.23 earnings per share for the current year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald increased their target price on shares of Exagen from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, May 14th.

Read Our Latest Stock Report on Exagen

Institutional Trading of Exagen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XGN. Perkins Capital Management Inc. increased its position in shares of Exagen by 92.8% during the fourth quarter. Perkins Capital Management Inc. now owns 508,905 shares of the company’s stock worth $1,013,000 after acquiring an additional 245,000 shares in the last quarter. Stonepine Capital Management LLC boosted its stake in Exagen by 14.7% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,203,491 shares of the company’s stock valued at $2,912,000 after purchasing an additional 154,139 shares during the last quarter. Finally, RTW Investments LP raised its stake in shares of Exagen by 0.8% in the fourth quarter. RTW Investments LP now owns 1,504,602 shares of the company’s stock worth $2,994,000 after purchasing an additional 12,170 shares during the last quarter. 75.25% of the stock is owned by institutional investors.

About Exagen

(Get Free Report)

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Read More

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with's FREE daily email newsletter.